1. Medtech Insight
  2. >>Business
  3. >>Deals

Pacts In Medtech: January/February 2017

 
• By Beth Allan, Deanna Kamienski, and Maureen Riordan

Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bi-monthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in January and February 2017.

Pacts In Medtech
Medtech co-operation and collaboration • Source: Shutterstock

The first two months of 2017 saw a flurry of alliances that involved Asian players, whose partnerships with western counterparts have noticeably risen in recent years. This is driven by companies in the west seeking to expand eastwards into emerging markets, namely China, while Asian companies are looking to bring in innovation developed abroad to meet growing domestic demand for quality health care solutions.

US molecular diagnostics firm Biodesix Inc. has licensed toBeijing Bioyong Technology Co. Ltd. the rights to develop and sell...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sofinnova And NVIDIA Partner To ‘Supercharge’ Computation For European Startups

 
• By Natasha Barrow

European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

More from Business